8-K ·Filed Jun 9, 2026

ESPR

Esperion Therapeutics, Inc.
BULLISH
Impact 6/10
Horizonweeks Processed3mo ago SEC0001104659-26-071814
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The German clearance removes a material condition precedent, increasing the probability of deal completion. Monitor the July 8 stockholder vote and any HSR developments. The stock should trade closer to the implied deal price as remaining conditions are resolved.

DirectionBullish
Confidencehigh
Horizonweeks
Latest settled — T+20d
ESPR ▲ +1.59% at T+20d
LONG call ✓ call won +1.59% · α vs SPY -2.03% · entry $3.14 → $3.19
Next anchor: T+60d due 29d ago
Latest observation: T+22 -4.49% FF3 residual α
Entry anchored
Jun 9, 03:59 PM ET
via exchange tick
T+1d
+0.32%
call +0.32% · α -1.38%
$3.15
settled 4mo ago
T+5d
+0.64%
call +0.64% · α -2.80%
$3.16
settled 4mo ago
T+20d
+1.59%
call +1.59% · α -2.03%
$3.19
settled 3mo ago
T+60d
—
call — · α —
—
due 29d ago

Price Chart

Loading chart...

Executive Summary

Esperion Therapeutics disclosed that the German Federal Cartel Office (Bundeskartellamt) cleared the pending acquisition by an affiliate of ArchiMed SAS, effective June 2, 2026. The merger remains subject to other conditions, including HSR clearance and stockholder approval at a special meeting scheduled for July 8, 2026.

Key Facts

  • Bundeskartellamt cleared the merger effective June 2, 2026.
  • Special stockholder meeting to vote on the merger is set for July 8, 2026.
  • Completion still requires HSR waiting period expiration/termination and stockholder adoption of the merger agreement.

Financial Impact

Removal of a key regulatory hurdle in Germany; deal value not disclosed in this filing.

Risk Factors

  • Stockholder vote may not pass.
  • HSR waiting period could be extended or challenged.
  • Other closing conditions may not be satisfied.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
0% bullish (11 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-071814
Document: 0001104659-26-071814-index-headers.html0001104659-26-071814
Document: 0001104659-26-071814-index.html0001104659-26-071814
Document: 0001104659-26-071814.txt0001104659-26-071814
20 reports for ESPR
Performance horizon
71% Hit rate 5 of 7 directional calls best @ T+60▲ +16.30%Mar 10, 2026
Filters
Rows
Reports for ESPR — sortable, filterable
TypeNow
Sep 3, 2026
29d ago
Court Ruling
BULLISH ★ 5/10
—awaiting T+5——
Aug 13, 2026
7w ago
Institutional Cluster
BEARISH ★ 5/10
—awaiting T+5——
Jul 23, 2026
10w ago
15-12G
NEUTRAL ★ 5/10
—awaiting T+5——
Jul 16, 2026
11w ago
EFFECT
BEARISH ★ 5/10
$3.18 awaiting T+5awaiting T+5——
Jul 16, 2026
11w ago
EFFECT
BEARISH ★ 5/10
$3.18 awaiting T+5awaiting T+5——
Jul 13, 2026
11w ago
25-NSE
BULLISH ★ 7/10
$3.19 awaiting T+5awaiting T+5——
Jul 13, 2026
11w ago
8-K
BULLISH ★ 7/10
$3.19 awaiting T+5awaiting T+5——
Jun 16, 2026
15w ago
DEFA14A
BULLISH ★ 6/10
$3.17 $3.15▼ −0.63%▲ +0.41%—
Jun 11, 2026
16w ago
Institutional Cluster
MIXED ★ 4/10
$3.15 $3.17▲ +0.63%▲ +0.20%—
Jun 9, 2026
16w ago
8-K
BULLISH ★ 6/10
$3.14 $3.16▲ +0.64%▼ −2.80%—
Showing 10 of 20

US Market Status

Market Closed — Opens Mon (38h 32m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access